If you discover you’re pregnant while taking semaglutide, the standard recommendation is to stop the medication immediately. Semaglutide has not been approved for use during pregnancy, and manufacturers of Ozempic, Wegovy, and Rybelsus all advise discontinuing the drug at least two months before a planned pregnancy. That said, early research on accidental exposures in humans paints a more nuanced picture than the worst-case fears might suggest.
What Animal Studies Show
Much of the concern around semaglutide and pregnancy comes from animal research. In studies on small animals exposed to GLP-1 receptor agonists during pregnancy, researchers observed decreased fetal growth, skeletal and organ abnormalities, and embryonic death. These findings are the primary reason the drug carries a pregnancy warning.
A closer look at the mechanism reveals why. When researchers activated GLP-1 receptors in pregnant animals during late gestation, fetal body weight dropped significantly, even when the mother’s blood sugar was restored to normal levels. The drug appeared to interfere directly with how the placenta functions. Specifically, it reduced the area of the placenta responsible for nutrient exchange, shrank the blood vessel network within that zone, and lowered levels of key nutrient transporters that move glucose and amino acids from mother to baby. In other words, the drug didn’t just affect the mother’s metabolism. It actively restricted the supply line to the developing fetus.
It’s worth noting that animal studies use controlled doses and timing that don’t perfectly mirror human pregnancies. But these results are the reason regulators take a cautious stance.
What We Know From Human Pregnancies
Human data is still limited, but a systematic review published in the European Journal of Obstetrics and Gynecology analyzed five studies covering 1,128 pregnancies with semaglutide exposure. The results were more reassuring than animal data alone might suggest.
One study found a spontaneous miscarriage rate of 23% among women exposed to GLP-1 receptor agonists. That sounds alarming on its own, but it was comparable to the rates seen in women with diabetes (26%) and women with obesity (29%) who weren’t taking the drug. Since most people taking semaglutide fall into one or both of those categories, the drug may not be adding meaningful risk on top of what the underlying condition already carries.
Major birth defects occurred in about 2.6% of the GLP-1 receptor agonist group, which was similar to the 2.3% rate in a diabetes comparison group. One study did find a higher overall rate of congenital malformations at 8.3%, but even that didn’t represent a statistically significant increase compared to women using insulin. The picture is far from complete, but so far, accidental early exposure hasn’t produced the dramatic spike in complications that animal studies might predict.
One notable finding: pregnancy termination rates were higher in the GLP-1 group (18%) compared to the diabetes group (6%). This likely reflects the anxiety surrounding an unplanned exposure rather than a difference in actual outcomes.
Why the Two-Month Washout Matters
Regulatory authorities and the manufacturers all converge on the same guidance: stop semaglutide at least two months before trying to conceive. This timeline exists because semaglutide has a long half-life, meaning it stays active in your body for roughly a week after each injection. A two-month gap gives the drug enough time to fully clear your system before an embryo begins developing.
For women using semaglutide for weight management, experts recommend using reliable contraception throughout treatment. If you’re thinking about pregnancy in the near future, the conversation about stopping the medication should happen well before you start trying. Fertility can actually increase on semaglutide. Weight loss improves ovulation in women with obesity-related subfertility, and there are widespread anecdotal reports of unexpected pregnancies on the drug. This is sometimes called the “Ozempic baby” phenomenon, and it means the need for contraception while on semaglutide is real, not theoretical.
What Happens If You Need to Stop Mid-Treatment
If you were taking semaglutide for type 2 diabetes and become pregnant, the question shifts to how you’ll manage blood sugar for the rest of your pregnancy. Insulin is the standard replacement. It has a long safety record in pregnancy and does not cross the placenta, meaning it won’t reach the developing baby. Your provider will work out a dosing plan tailored to your glucose levels and how far along you are.
If you were taking semaglutide purely for weight loss, the transition is simpler. You stop the drug, and the focus shifts to adequate nutrition and appropriate weight gain during pregnancy. Because semaglutide suppresses appetite so effectively, some women may have been eating significantly less than usual before discovering the pregnancy. Making sure you’re getting enough calories, protein, and key nutrients like folate and iron becomes a priority once the medication is out of the picture.
Breastfeeding After Semaglutide Use
There is very little data on whether semaglutide passes into breast milk or what effect it might have on a nursing infant. The manufacturers recommend against using it while breastfeeding. If you stopped the drug during pregnancy, the two-month clearance window means it will be long gone from your system by the time your baby arrives. If you’re considering restarting after delivery, the timing depends on whether you plan to breastfeed and how long.
Putting the Risk in Perspective
Discovering a pregnancy while on semaglutide is understandably frightening, especially if you’ve read about the animal data. But the human evidence so far suggests that early, accidental exposure does not carry the same level of risk seen in animal models. Miscarriage and birth defect rates in exposed pregnancies have been roughly comparable to those in women with similar health profiles who weren’t on the drug.
That doesn’t mean the drug is safe during pregnancy. It means that if you’ve already been exposed, the odds are still in your favor for a healthy outcome. The most important step is stopping the medication as soon as you know, letting your provider know about the exposure, and shifting to pregnancy-appropriate management of any conditions the semaglutide was treating.